Park Medi World
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Park Medi World Ltd is strategically positioned for robust growth, driven by an aggressive expansion plan aimed at increasing bed capacity from 3,960 to 10,000 by FY33. Management's focus on enhancing operational efficiency through a cluster-based model and reducing reliance on government schemes is expected to improve margins and revenue growth. The company anticipates a 35.3% revenue CAGR through FY29, supported by rising demand for organized healthcare in Tier 2 and Tier 3 markets. Despite potential risks associated with rapid scaling and integration of new assets, the disciplined capital allocation and strong balance sheet provide a solid foundation for long-term value creation. Vista's financial outlook reflects stable margins and a fair valuation, with an expected upside of approximately 30%. The healthcare sector's stable pricing power and ongoing demand for quality services further bolster this outlook. Over the next 12-24 months, key opportunities include successful execution of expansion plans and capturing market share in underserved regions, while watchpoints include regulatory challenges and maintaining high utilization rates during growth phases
Why We Like This Stock
- Aggressive expansion strategy targeting a bed capacity increase to 10,000 by FY33
- Shift towards higher-margin tertiary care and reduced reliance on government schemes enhances revenue potential
- Strong operational momentum and a disciplined capital allocation strategy support long-term value creation
Things To Watch Out For
- Execution risks associated with rapid scaling and integration of new assets could impact operational efficiency
- Potential regulatory challenges may affect pricing and reimbursement structures
- High working capital requirements due to the current patient mix may pressure cash flows
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,231 | 1,394 | 1,679 | 1,992 | 2,247 |
| Profit Before Tax (Cr.) | 220 | 289 | 355 | 439 | 493 |
| PBT Margin | 17.9% | 20.7% | 2114.4% | 22.0% | 21.9% |
| Net Profit (Cr.) | 137 | 208 | 274 | 338 | 359 |
| Earnings Per Share | 3.2 | 4.6 | 6.0 | 7.4 | 8.3 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Choice Equity | ▲ Buy | 350 | 04-Aug-2026 |
| Emkay Global | ▲ Buy | 350 | 19-Jun-2026 |
Company Overview
Show Company Profile
Park Medi World Limited operates a network of hospitals. The company provides cardiac sciences, neurosciences - brain and spine, plastic and cosmetic surgery, general and laparoscopic surgery, renal sciences and kidney transplant, bone, orthopaedics, joint replacement and sports medicine, gastroenterology and surgical gastroenterology, cancer care, bone marrow transplant, iMARS / robot-assisted surgery. It also offers bariatric surgery, anaesthesiology, critical care, chest and respiratory diseases, dental care, dermatology, endocrinology, paediatrics, internal medicine and geriatrics, rheumatology, ENT, ophthalmology, obstetrics and gynaecology, interventional radiology and imaging, psychiatry, pathology and microbiology, paediatric surgery, fertility management, nuclear medicine services. It operates NABH accredited multi-super specialty hospitals under the Park brand name. Park Medi World Limited was founded in 2005 and is headquartered in Gurugram, India.